Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
about
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisEmerging drugs for moderate-to-severe psoriasis.New drugs in the treatment of psoriasis.The immunologic effects of estrogen on psoriasis: A comprehensive review.Activation of the IL-10 gene promoter following photodynamic therapy of murine keratinocytesThe treatment of psoriasis with IL-10: rationale and review of the first clinical trials.Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implicationsType 1/Type 2 immunity in infectious diseases.Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection.Progress in understanding the immunopathogenesis of psoriasisSleep loss and cytokines levels in an experimental model of psoriasis.Cytokine therapy in dermatology.Cytokines: interleukin and interferon therapy in dermatology.Biological response modifiers and their potential use in the treatment of inflammatory skin diseases.The role of T cells in psoriasis.Genetic basis of psoriasis vulgaris and its pharmacogenetic potential.Targeting cytokines in autoimmunity: new approaches, new promise.The immunological basis of psoriasis.Novel biological immunotherapies for psoriasis.Cytokine and anticytokine therapy in dermatology.Evolution of biologic therapies for the treatment of psoriasis.Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.Novel biologic therapies for psoriasis.Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infectionInterleukin-10 in viral diseases and cancer: exiting the labyrinth?Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?Novel pharmacological approaches in the treatment of psoriasis.PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.Design of a covalently linked human interleukin-10 fusion protein and its secretory expression in Escherichia coli.Distinct roles of trauma and transfusion in induction of immune modulation after injury.Biologic agents in psoriasis.Interrelationship among asthma, atopy, and helminth infections.Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation.PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDOPegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity.Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells.Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression.Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis.Leflunomide in the treatment of psoriasis: results of a phase II open trial.Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ.
P2860
Q28482161-E47BBEB6-6B3D-4B30-9AFD-AFAFAE6680AEQ30984470-2ADA1410-D53A-4D84-AABF-A5BD773662CCQ33181382-E1CE6741-EB05-4845-BEA3-5ADEDAA750E9Q33640627-07548CD9-4AAD-4E6F-980D-0D460055F6C4Q34056351-AB4F0C7F-28CB-473E-BF6D-E5DF4D2D1325Q34074672-46B38B4E-8EAD-4FE8-A9F4-AAB3C639208FQ34099814-1C099619-263E-4BBC-8C1F-70AD82E94975Q34105379-0F2D7CF1-DC8D-44A9-BBEF-45B22C624088Q34185923-BCD0CAF6-A5BA-415F-ADAC-D34DA479EB16Q34215381-B86A7A46-79CD-4D00-8F48-C36054D83F94Q34506348-47206A69-4A09-475C-BFCC-63AA6FAD0948Q34626999-41E32E78-EB64-465F-9126-2E6CDE10CA0BQ35015856-BBA8FC37-4858-4125-BF49-2A6CED5997C0Q35083650-6D74DD60-B81D-48DC-9275-6F34C9F78743Q35110104-21BD73B9-F87D-4E21-9CCE-CCC362E28F85Q35116099-12BB2ACE-BCE3-411D-B36D-649C34BB44B4Q35144028-87FED80A-C505-4470-805F-F71017AF02D0Q35149415-B9ECCE07-B497-45D6-8687-CA26E345D26AQ35164740-CCA14C9F-AB43-4E52-8EED-9238F3212B5FQ35184711-CE54FC3D-462E-4D8D-A48B-87291647019FQ35606903-5A2FB695-5589-42BE-B1E9-E65913D7D212Q35680472-EC6260BA-678C-4BDF-BD45-1969E81EB03AQ35790897-DE7B133F-4491-445D-B6A9-476BFFE09AA8Q35831296-B6ED1348-1FFF-427B-BC5D-19C6F2BF7A74Q35951835-AFABC0F2-AE81-4A08-9300-5D964898C5D0Q35951845-54B62E2F-2BFD-4AEE-8524-A3CCC5AD4E5AQ36008673-E41B7C59-F7AC-41C4-9CEE-C456F0069EB1Q36051650-666C9935-EB4E-4F9C-861F-0417E742A39CQ36080839-2653D228-5121-4585-9B3A-537360D0F514Q36084211-438DB2EC-5440-418F-B465-3E7A91093EA1Q36620700-FC81CAF0-09F5-4B59-95ED-EC65E37EF5D3Q36956282-368CC1F9-9680-48B0-A410-94AB7D52114BQ37176336-54DD621C-D11A-45D7-9E75-B802AEF713F7Q37222162-1269BE44-ECD3-428C-AAA6-A73C4D931801Q38105994-7BC98F4F-8685-4001-BD11-9E6165DDD791Q38352602-FC767A62-29E0-4D0B-B8E2-95933F0571E8Q40654300-B46210A1-726C-45D4-9A54-C8C94F3B30DAQ40868178-5BE1C9C5-4C84-4494-830F-19F3EB104149Q42627416-F68CF071-C90C-4B6C-BEB9-5D8E18713453Q44354351-4384A385-3AA6-421B-9851-32FDA8678122
P2860
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@ast
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@en
type
label
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@ast
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@en
prefLabel
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@ast
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@en
P2093
P1433
P1476
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
@en
P2093
Asadullah K
Friedrich M
P304
P356
10.1001/ARCHDERM.135.2.187
P577
1999-02-01T00:00:00Z